Ghost Tree Capital LLC cut its holdings in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) by 34.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,315,154 shares of the company's stock after selling 684,846 shares during the period. Ghost Tree Capital LLC owned about 0.64% of VistaGen Therapeutics worth $1,631,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of VTGN. Advisor Group Holdings Inc. increased its stake in VistaGen Therapeutics by 45.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 42,696 shares of the company's stock worth $83,000 after purchasing an additional 13,255 shares during the period. ProShare Advisors LLC grew its position in shares of VistaGen Therapeutics by 70.8% during the fourth quarter. ProShare Advisors LLC now owns 42,391 shares of the company's stock worth $82,000 after buying an additional 17,568 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of VistaGen Therapeutics by 299.9% during the fourth quarter. Principal Financial Group Inc. now owns 149,035 shares of the company's stock worth $291,000 after buying an additional 111,765 shares in the last quarter. Rafferty Asset Management LLC grew its position in shares of VistaGen Therapeutics by 98.8% during the fourth quarter. Rafferty Asset Management LLC now owns 490,295 shares of the company's stock worth $956,000 after buying an additional 243,612 shares in the last quarter. Finally, Eagle Asset Management Inc. acquired a new position in shares of VistaGen Therapeutics during the fourth quarter worth about $30,000. 77.10% of the stock is currently owned by hedge funds and other institutional investors.
Get
VistaGen Therapeutics alerts:
VistaGen Therapeutics Stock Up 5.8 %
Shares of VTGN opened at $0.21 on Friday. The stock has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.91. VistaGen Therapeutics, Inc. has a 52-week low of $0.14 and a 52-week high of $3.22.
VistaGen Therapeutics (NASDAQ:VTGN – Get Rating) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). The business had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.34 million. VistaGen Therapeutics had a negative net
margin of 5,614.37% and a negative return on equity of 88.13%. Research analysts anticipate that VistaGen Therapeutics, Inc. will post -0.27 EPS for the current year.
Insider Activity at VistaGen Therapeutics
In other VistaGen Therapeutics news, major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business's stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $0.89, for a total value of $53,400.00. Following the completion of the sale, the insider now owns 20,637,286 shares in the company, valued at $18,367,184.54. The sale was disclosed in a document filed with the SEC, which is available through this link. In other VistaGen Therapeutics news, major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business's stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $0.89, for a total value of $53,400.00. Following the completion of the sale, the insider now owns 20,637,286 shares in the company, valued at $18,367,184.54. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Reid G. Adler acquired 300,000 shares of VistaGen Therapeutics stock in a transaction on Wednesday, August 17th. The stock was purchased at an average price of $0.17 per share, with a total value of $51,000.00. Following the purchase, the insider now owns 334,629 shares of the company's stock, valued at approximately $56,886.93. The disclosure for this purchase can be found here. Insiders acquired 1,000,000 shares of company stock valued at $171,000 over the last three months. 4.01% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
VTGN has been the subject of a number of analyst reports. Maxim Group downgraded VistaGen Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, July 26th. William Blair downgraded VistaGen Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Friday, July 22nd. Jefferies Financial Group downgraded VistaGen Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, July 22nd. Finally, Robert W. Baird downgraded VistaGen Therapeutics from an "outperform" rating to a "neutral" rating in a research report on Friday, July 22nd.
VistaGen Therapeutics Company Profile
(Get Rating)
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.
Further Reading
- Get a free copy of the StockNews.com research report on VistaGen Therapeutics (VTGN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
